Chelsee J. Jensen, PharmD, BCPS

FDA accelerated approval speeds access but faces challenges with trial completion, costs, and end point validation.

Health systems must have a flexible workflow in place to allow the use of non-preferred agents to accommodate payer demands and reduce financial toxicity.